Impact of HDAC inhibitors on dendritic cell functions
Jihane Frikeche1, Zinaida Peric, Eolia Brissot
1INSERM CRNCA UMR892, Nantes, France.
Abstract:
Histone deacetylase inhibitors are presently used in the routine clinic treatment against cancers. Recent data have established that some of these treatments have potent anti-inflammatory or immunomodulatory effects at noncytotoxic doses that might be of benefit in immuno-inflammatory disorders or post-transplantation. At least some of these effects result from the ability of histone deacetylase inhibitors to modulate the immune system. Dendritic cells are professional antigen presenting cells that play a major role in this immune system. Data summarized in this review brings some novel information on the impact of histone deacetylase inhibitors on dendritic cell functions, which may have broader implications for immunotherapeutic strategies.
Insights
Histone deacetylase inhibitors show promise beyond cancer treatment, offering anti-inflammatory benefits for immune disorders. These drugs modulate dendritic cell function, potentially enhancing immunotherapies.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Histone deacetylase inhibitors (HDACi) are established cancer therapeutics.
- Emerging evidence suggests HDACi possess anti-inflammatory and immunomodulatory properties at non-cytotoxic doses.
- These effects are linked to HDACi's ability to modulate immune system components.
Purpose of the Study:
- To review the impact of histone deacetylase inhibitors on dendritic cell functions.
- To explore the potential of HDACi in treating immuno-inflammatory disorders and in post-transplantation settings.
- To highlight the implications for future immunotherapeutic strategies.
Main Methods:
- Literature review of studies investigating histone deacetylase inhibitors and immune cell function.
- Analysis of data on the effects of HDACi on dendritic cell biology.
- Synthesis of findings related to immunomodulation and therapeutic applications.
Main Results:
- Histone deacetylase inhibitors can significantly impact dendritic cell functions.
- These modulations may contribute to the observed anti-inflammatory and immunomodulatory effects of HDACi.
- Dendritic cells play a crucial role in the immune responses influenced by HDACi.
Conclusions:
- Histone deacetylase inhibitors offer potential therapeutic benefits for immuno-inflammatory conditions.
- Targeting dendritic cell function with HDACi could represent a novel immunotherapeutic approach.
- Further research into HDACi's immunomodulatory effects is warranted for clinical translation.
